Regeneron (REGN) Pharmaceuticals announced that the U.S. Food and Drug Administration, FDA, has accepted for review the resubmission of the Biologics License Application, BLA, for odronextamab in relapsed/refractory follicular lymphoma, FL, after two or more lines of systemic therapy. The target action date for the FDA decision is July 30, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Promising Developments and Strategic Positioning Justify Buy Rating for Regeneron
- Regeneron announces updated DB-OTO data from CHORD trial
- Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA
- QQQ ETF News, 2/17/2025
- Guggenheim lowers Regeneron price target, says selloff ‘overdone’